The present disclosure provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: dimethyl sulfoxide (DMSO), disaccharide, human serum, and IL-7 and/or IL-15. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 10 w/v % and 90 w/v % human serum. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 0.5 w/v % and 30 w/v % human serum albumin.

An organ preservation system having; an organ chamber with a perfusate reservoir, a pump arranged to circulate perfusate, from the reservoir and passes the perfusate through a dialysis filter, oxygenator, and temperature and pressure sensors prior to entering the chamber where an organ is perfused. The organ rests on the platform such that perfusate leaving the organ flows into the perfusate reservoir. The dialysis filter having permeable tubes which allow perfusate constituents to be exchanged with dialysate flowing through the dialysis filter. The dialysate pass through an ion exchange resin removing selected constituents or waste products from the dialysate by absorption by the ion exchange resin. Following waste absorption, the dialysate is recycled to the dialyzer to again remove waste. Removing waste products from the perfusate by dialysis followed by removal of the waste products from the dialysate with the exchange resin, enables dialysate reuse for extended duration.

Human induced pluripotent stem cells (hiPSCs) possess tremendous potential for tissue regeneration and banking hiPSCs by cryopreservation for their ready availability is crucial to their widespread use. However, contemporary methods for hiPSC cryopreservation are associated with both limited cell survival and high concentration of toxic cryoprotectants and/or serum. The latter may cause spontaneous differentiation and introduce xenogeneic factors, which may compromise the quality of hiPSCs. Here, sand from nature is discovered to be capable of seeding ice above 10 C., which enables cryopreservation of hiPSCs with no serum, minimized cryoprotectant, and high cell survival. Furthermore, the cryopreserved hiPSCs retain high pluripotency and functions judged by the pluripotency marker expression, cell cycle analysis, and capability of differentiation into the three germ layers. This unique sand-mediated cryopreservation method may greatly facilitate the convenient and ready availability of high-quality hiPSCs and probably many other types of cells/tissues for the emerging cell-based translational medicine.

The present invention relates to a storage stabilization agent for stabilizing an aqueous composition upon storage comprising at least two different water soluble or water dispersible ion sources selected from the group consisting of water soluble or water dispersible source of bismuth ions, water soluble or water dispersible source of magnesium ions, water soluble or water dispersible source of sodium ions, water soluble or water dispersible source of potassium ions and water soluble or water dispersible source of zinc ions. Furthermore, the present invention relates to an aqueous preparation comprising the storage stabilization agent, a process for stabilizing an aqueous preparation upon storage as well as the use of the storage stabilization agent for stabilizing the pH value of an aqueous preparation or preventing microorganisms as well as viruses and/or bacteriophages from growing or both.

Described are systems, methods, and devices relating to normothermic extracorporeal support of an organ, tissue, or bioengineered graft comprising cross-circulation (XC) perfusion for prolonged periods (days to weeks) via an XC perfusion circuit in connection with an extracorporeal host (e.g., animal, patient, organ transplant recipient) are disclosed. The XC perfusion circuit comprises auto-regulation of blood flow based on the trans-organ blood pressure difference between arterial and venous pressure. Recipient support enabled 36 h of normothermic perfusion that maintained healthy lungs with no significant changes in physiologic parameters and allowed for the recovery of injured lungs. Extended support enabled multiscale therapeutic interventions in all extracorporeal lungs. Lungs exceeded transplantation criteria.

Described are systems, methods, and devices relating to normothermic extracorporeal support of an organ, tissue, or bioengineered graft comprising cross-circulation (XC) perfusion for prolonged periods (days to weeks) via an XC perfusion circuit in connection with an extracorporeal host (e.g., animal, patient, organ transplant recipient) are disclosed. The XC perfusion circuit comprises auto-regulation of blood flow based on the trans-organ blood pressure difference between arterial and venous pressure. Recipient support enabled 36 h of normothermic perfusion that maintained healthy lungs with no significant changes in physiologic parameters and allowed for the recovery of injured lungs. Extended support enabled multiscale therapeutic interventions in all extracorporeal lungs. Lungs exceeded transplantation criteria.

Described herein are blood storage containers that can contain a CeONP composition and/or coating on an object surface. In some aspects, the blood storage container can include an insert. In some aspects the inserts can contain a CeONP compositions and/or coating on an object surface. In aspects, the CeONP composition and/or coating on an object surface can be effective to increase the useful storage lifespan of blood, blood product, and/or component thereof stored in the blood storage container. Also described herein are methods of making and using the CeONP compositions, coatings, and devices containing the CeONP compositions and/or coatings described herein.

Methods, additive kits and storage compositions for decreasing the deleterious effects of storage on pRBCs, for improving the aging process of stored pRBCs, and for preventing or ameliorating patient comorbidities following the transfusion or infusion of stored blood based on inhibiting acid sphingomyelinase during storage are provided.

Methods, additive kits and storage compositions for decreasing the deleterious effects of storage on pRBCs, for improving the aging process of stored pRBCs, and for preventing or ameliorating patient comorbidities following the transfusion or infusion of stored blood based on inhibiting acid sphingomyelinase during storage are provided.

Described are systems, methods, and devices relating to normothermic extracorporeal support of an organ, tissue, or bioengineered graft comprising cross-circulation (XC) perfusion for prolonged periods (days to weeks) via an XC perfusion circuit in connection with an extracorporeal host (e.g., animal, patient, organ transplant recipient) are disclosed. The XC perfusion circuit comprises auto-regulation of blood flow based on the trans-organ blood pressure difference between arterial and venous pressure. Recipient support enabled 36 h of normothermic perfusion that maintained healthy lungs with no significant changes in physiologic parameters and allowed for the recovery of injured lungs. Extended support enabled multiscale therapeutic interventions in all extracorporeal lungs. Lungs exceeded transplantation criteria.